Business Wire

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies ...
Seeking Alpha

Syros: Multiple Shots On Goal In Blood Cancer Space

The first clinical program to go over involves the use of Tamibarotene for the treatment of patients with newly diagnosed High-Risk Myelodysplastic Syndrome. Myelodysplastic Syndrome (MDS) involves a ...
Morningstar

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the ...
Seeking Alpha

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Syros Pharmaceuticals is a cancer-focused biotech working on therapies for blood cancer, with a main drug in development. The company's main program is tamibarotene, targeting specific myeloid cancers ...
Nasdaq

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical ...

Combination of tamibarotene and azacitidine in a Phase 2 trial demonstrated a high complete response rate, with rapid onset and clinically meaningful durability in newly diagnosed unfit acute myeloid ...
Benzinga.com

Why Is Blood Cancer Focused Syros Pharmaceuticals Stock Soaring Today?

Syros Pharmaceuticals Inc (NASDAQ:SYRS) released initial data from its ongoing SELECT-AML-1 Phase 2 trial of tamibarotene in combination with venetoclax and azacitidine in newly diagnosed, unfit ...